Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Sudarshan Sukhani of s2analytics.com recommends selling metal stocks and PSU banking stocks.
Kunal Saraogi of Equityrush suggests buying Motherson Sumi with a target of Rs 285.
Shubham Agarwal of Motilal Oswal Securities recommends buying Petronet LNG for a target of Rs 290.
Prakash Gaba of prakashgaba.com recommends shorting Hero Motocorp and feels that PNB can test Rs 100.
VK Sharma of HDFC Securities advises buying Sun Pharma 840 Call and ONGC 245 Call.
According to Sudarshan Sukhani of s2analytics.com, the correction in pharmaceutical stocks would be an opportunity.
According to Ambareesh Baliga, Market Expert, one can prefer Lupin from pharma space.
Kunal Bothra of LKP Securities is of the view that Sun Pharma has resistance around Rs 840-850.
Basant Maheshwari, Founder of The Equity Desk And Author of The Thoughtful Investor is of the view that one may prefer pharma stocks.
Bhavin Desai of Motilal Oswal Securities is of the view that one may avoid pharma stocks.
Mayuresh Joshi of Angel Broking is positive on Sun Pharmaceutical Industries.
According to Sudarshan Sukhani of s2analytics.com, Aurobindo Pharma, Lupin and Divis Laboratories are investment ideas.
Prakash Gaba of prakashgaba.com is of the view that one may buy Jubilant Foodworks.
Rajat Bose of rajatkbose.com advises buying Reliance Communications.
According to SP Tulsian of sptulsian.com, Sun Pharmaceutical Industries is a good trading bet in Rs 750-830 range.
Mayuresh Joshi of Angel Broking is of the view that one may look at Sun Pharmaceutical Industries.
Prakash Gaba of prakashgaba.com is of the view that Oil and Natural Gas Corporation may test Rs 240.
Here are top 10 stocks picked up by CNBC-TV18's analysts in trade today - IDBI Bank, Indiabulls Real Estate, Marksans Pharma, Marico, NBCC, Sun Pharma, Interglobe Aviation, Cadila, HDIL, Eros International, Godrej Properties and Raymond.
Mayuresh Joshi of Angel Broking is of the view that one may prefer Sun Pharmaceutical Industries with long term view.
Ajay Srivastava, CEO at Dimensions Consulting is of the view that one may prefer pharma stocks with long term view.
Sandip Sabharwal of asksandipsabharwal.com is of the view that one may look at Sun Pharmaceutical Industries.
In an interview to CNBC-TV18, Surya Narayan Patra of PhillipCapital shared his readings and outlook on Sun Pharmaceutical Industries and also spoke about the warning letter which the company has received from USFDA.
Sudarshan Sukhani of s2analytics.com suggests buying Sun Pharmaceutical on dips.
VK Sharma of HDFC Securities recommends buying Sun Pharma 800 Call.
Gaurav Bissa of LKP Securities recommends buying Marico with a target of Rs 450 and Sun Pharma with a target of Rs 820.